Intravenous Immunoglobulin – How to use it
Authors:
- Jane PritchardJPJane Pritchard
- Richard A.C. HughesRHRichard A.C. Hughes
Open Access
- 1 December 2001
- journal article
- Published by BMJ in Practical Neurology
- Vol. 1 (2) , 93-97
Abstract
WHAT IS IT? The immunoglobulin used in intravenous immunoglobulin (IVIg) is prepared from the pooled plasma from about 8000 blood donors. Plasma purification includes steps to remove viruses. Donors at risk for transfusion-related viruses are excluded and IVIg consists almost entirely of IgG with traces of IgM, IgA and soluble plasma factors including cytokines. Its initial use was as replacement therapy in hypogamma-globulinaemia. Its success in treating autoimmune thrombocytopenic purpura led to its use in other immune-mediated diseases. HOW DOES IT WORK? We do not really know. There are many proposed mechanisms. Different, possibly multiple, mechanisms may apply in different diseases (Fig. 1). WHO NEEDS IT? Guillain–Barré Syndrome (GBS) and Kawasaki disease are the only neurological conditions licensed for IVIg treatment in the United Kingdom. The strength of the evidence for the use of IVIg in other neurological conditions varies. Consensus does not exist. Tables 1, 2 and 3Keywords
This publication has 8 references indexed in Scilit:
- Immunomodulation of Autoimmune and Inflammatory Diseases with Intravenous Immune GlobulinNew England Journal of Medicine, 2001
- Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathyAnnals of Neurology, 2001
- Multifocal motor neuropathyJournal of Neuroimmunology, 2001
- Anti-inflammatory Activity of IVIG Mediated Through the Inhibitory Fc ReceptorScience, 2001
- Nephrotoxicity of intravenous immunoglobulinQJM: An International Journal of Medicine, 2000
- Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: Present status and practical therapeutic guidelinesMuscle & Nerve, 1999
- Treatment of Kawasaki syndrome: A comparison of two dosage regimens of intravenously administered immune globulinThe Journal of Pediatrics, 1990